Largest real-world psychedelic study launches to track mental health, wellbeing, and outcomes across naturalistic use at unprecedented global scale

A large real-world psychedelic study is recruiting participants to measure mental health, wellbeing, and lasting effects across naturalistic use outside laboratory settings. The project aims to capture what happens before and after psychedelic experiences at a scale that controlled clinical trials rarely reach. Researchers are gathering repeated self-report data from people planning to use substances such as psilocybin, LSD, MDMA, ketamine, ayahuasca, and DMT in everyday contexts. The design focuses on baseline measures, follow-up assessments, and patterns that may link set, setting, intention, and support with positive or negative outcomes. Naturalistic evidence could broaden understanding of who benefits, who is at risk, and how real-world use differs from tightly screened therapeutic studies. The findings may help shape harm reduction, future clinical research, and public discussion as psychedelic use moves further into the mainstream.